Loading
A phase 2 trial of Abemaciclib and Temozolomide in glioma & glioblastoma, run by Eli Lilly and Company, active and no longer recruiting.
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy is a phase 2 interventional study registered as NCT06413706 by Eli Lilly and Company, with 45 participants enrolled, started 2024-10-25 and due to reach its primary completion in 2027-02. Interventions recorded: Abemaciclib and Temozolomide.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors, Temozolomide and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.